PROTALIX BIOTHERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. PROTALIX BIOTHERAPEUTICS INC has strong liquidity. Currently, the Quick Ratio is 1.87 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 82.12% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||5.1||7.38|
|Net Income ($mil)||-5.97||-7.35|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||47.96||77.69|
|Total Assets ($mil)||72.05||103.42|
|Total Debt ($mil)||67.57||67.15|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||-82.93||-76.39|
|Return on Assets||-39.65||-29.79|
|Return on Equity||0.0||0.0|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||93.6||93.61|
|Div / share||0.0||0.0|
|Book value / share||-0.65||-0.36|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||315813.0||193328.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|PLX NM||Peers 60.93||PLX NM||Peers 60.74|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PLX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PLX's P/CF is negative making the measure meaningless.
|PLX NA||Peers 24.58||PLX NA||Peers 0.74|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PLX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PLX NM||Peers 12.32||PLX 6.07||Peers 18.47|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PLX's P/B is negative making this valuation measure meaningless.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, PLX is expected to significantly trail its peers on the basis of its earnings growth rate.
|PLX 12.44||Peers 423.45||PLX -13.76||Peers 355.26|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PLX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
PLX significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV